Benjamin Cowen, Phd, Mba

Benjamin Cowen, Phd, Mba Email and Phone Number

Chief Executive Officer I Company Builder I Board Director @ ImmunoMet Therapeutics, Inc.
houston, texas, united states
Benjamin Cowen, Phd, Mba's Location
Greater Philadelphia, United States
Benjamin Cowen, Phd, Mba's Contact Details

Benjamin Cowen, Phd, Mba personal email

About Benjamin Cowen, Phd, Mba

A Chief Executive Officer, Director and Life Sciences Executive with 25 years experience in biotechnology and pharmaceutical companies with broad background spanning Operations, Business Development, Finance, Strategic Planning, R&D Portfolio Management, Marketing and Sales. Lauded for strong working relationships and received recognition for high performance in every functional area. Established track record of building, leading and contributing to high performing teams.As CEO of ImmunoMet Therapeutics, built management team, raised ~$30 million in financing and progressed a first and best in class OXPHOS inhibitor through two successful Phase 1 studies and into a Phase 2 study in pancreatic cancer at MD Anderson Cancer Center.Currently CEO of TicTwo Therapeutics, a pre-clinical stage biotech developing TYK2 inhibitors targeting immune-mediated diseases. TicTwo is a spin-off from Alembic Pharmaceuticals, the oldest pharmaceutical company in India, and has been seeded with ~ $10 million from Alembic. The Company’s lead molecule is a topical formulation of a small molecule for psoriasis that could have the efficacy of oral agents and could significantly impact the mild and moderate segments of psoriasis.

Benjamin Cowen, Phd, Mba's Current Company Details
ImmunoMet Therapeutics, Inc.

Immunomet Therapeutics, Inc.

View
Chief Executive Officer I Company Builder I Board Director
houston, texas, united states
Website:
immunomet.com
Employees:
11
Benjamin Cowen, Phd, Mba Work Experience Details
  • Tictwo Therapeutics, Inc.
    President, Ceo And Co-Founder
    Tictwo Therapeutics, Inc. Oct 2023 - Present
    Philadephia, Pa
    TicTwo is a spin-off from Alembic Pharmaceuticals, the oldest pharmaceutical company in India, and has been seeded with ~ $10 million from Alembic. The Company’s lead molecule is a topical formulation of a small molecule for psoriasis that could have the efficacy of oral agents and could significantly impact the mild and moderate segments of psoriasis.
  • Immunomet Therapeutics, Inc.
    Board Director
    Immunomet Therapeutics, Inc. Feb 2018 - Present
    Houston, Texas
    ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. ImmunoMet's lead molecule, IM156, is a protein complex 1 (PC1) inhibitor which targets the OXPHOS pathway in mitochondria. IM156 is a first in class and best in class molecule.ImmunoMet has initiated a Phase 2 study in pancreatic cancer at MD Anderson Cancer Center (MDACC) and is planning a second Phase 2 study in metastatic melanoma at MGH and MDACC.
    View
  • Ceramedix Oncology
    Consultant Ceo
    Ceramedix Oncology May 2023 - Oct 2023
    New York, New York
    Ceramedix Oncology is a seed stage biotech developing novel antibodies that increase the efficacy of chemotherapies. The company is based on utilizing an endothelial cell signaling pathway discovered and extensively researched at the Memorial Sloan Kettering Cancer Center (MSK). Prepared the Company for institutional funding:• Significantly revised and strengthened their corporate presentation pitch deck • Created robust 5 yr budget for fundraising• Identified gaps in their Clinical Development Plan and addressed them• Facilitated company acceptance and entry into JLABS@NYC
  • Immunomet Therapeutics
    President And Ceo
    Immunomet Therapeutics Feb 2019 - May 2022
    Houston, Texas Area
    Transformed ImmunoMet from an R&D organization into a clinical stage biotech company: • Built a management team in first year, a C-suite in second year and continued to build and strengthen the executive management team each year.• Raised ~ $30 M from existing investors, new VC and public companies.• Successfully progressed lead molecule through two Phase 1 trials: one in oncology and second in healthy volunteers to support a new therapeutic area.• Set the corporate strategy to focus on oncology and fibrosis.• Defined the company’s core values and established the company’s culture.
  • Immunomet Therapeutics
    Chief Executive Officer
    Immunomet Therapeutics Nov 2017 - Feb 2019
  • Immunomet Therapeutics
    Chief Operating Officer
    Immunomet Therapeutics Nov 2016 - Oct 2017
  • Incon Co., Ltd
    Board Director
    Incon Co., Ltd Aug 2018 - Aug 2020
    Seoul, Korea
    INCON is a public company on Korean stock exchange transitioning to a healthcare holding company
  • Atrin Pharmaceuticals
    Board Director
    Atrin Pharmaceuticals Aug 2012 - Aug 2018
    Led $400K Family and Friends seed round of funding.Managed company finances and operations during start-up.
  • Milestone Pharmaceuticals
    Vice President, Corporate Development
    Milestone Pharmaceuticals Jan 2015 - Oct 2016
    Milestone Pharmaceuticals was a private VC backed biotech company (now public) developing a breakthrough therapy for paroxysmal supra-ventricular tachycardia (PSVT), a serious electrical disorder of the heart. Milestone’s lead product, etripamil, is a novel intranasal calcium channel blocker that will provide PSVT patients with a convenient, safe, and rapidly effective therapy that they can self-administer at the onset of an episode. Etripamil was in a Phase 2 POC study. (Milestone completed NASDAQ IPO in 2019).Led Business Development, Commercial and awareness activities. Played key role in successful $17 M Series B financing round led by Domain Associates.
    View
  • Pds Biotechnology
    Vice President, Business Development
    Pds Biotechnology Apr 2013 - Dec 2014
    PDS Biotechnology was a clinical stage private biopharmaceutical company (now public) that has developed a novel cancer immunotherapy platform vector, Versamune, and is initially applying the platform vector to the treatment of HPV related cancers.Led partnering activities and played key role in fundraising for the Phase 2 clinical program.
  • Shire Pharmaceuticals
    Sr. Director, Portfolio Management And Business Planning
    Shire Pharmaceuticals May 2011 - Jun 2012
    Led Portfolio Management and Business Planning for Shire Specialty Pharmaceuticals.
    View
  • Merck
    Director, Us Business Development
    Merck 2008 - 2011
    Led teams for search, evaluation and transactional activities in support of the Oncology, Cardiovascular, Diabetes and Dermatology Commercial Franchises.
  • Merck
    Oncology Franchise Portfolio Associate Director
    Merck 2006 - 2008
    Performed portfolio analysis and provided recommendations to ensure that the allotment and utilization of R&D Oncology resources were aligned with R&D Oncology Franchise strategy
  • Merck
    Associate Marketing Manager/Promotion Manager
    Merck 2004 - 2006
    Developed promotional strategies and tactics for Primaxin® (antibacterial) and Invanz® (antibacterial). Launched two new indications for Invanz®: diabetic foot and pediatric.
  • Merck
    Health Science Liaison (Medical Science Liaison)
    Merck 2002 - 2004
    Built relationships and drove scientific issues with HIV Key Opinion Leaders in PA, MD, DE, DC, VA and OH. Conducted over 700 calls with Key Opinion Leaders per year.
  • Merck
    Hiv Sales Specialist
    Merck 2000 - 2002
    Promoted Crixivan® (HIV) and launched Cancidas® (anti-fungal) to HIV providers in hospitals, clinics and private offices in Philadelphia and Lehigh Valley.
  • Merck
    Business Develop & Strategic Planning Analyst
    Merck 1997 - 2000
    Performed financial modeling and risk/opportunity analyses of business development deals and evaluated potential industry mergers.

Benjamin Cowen, Phd, Mba Skills

Pharmaceutical Industry Biotechnology Oncology Strategy Vaccines Life Sciences Cross Functional Team Leadership Diabetes Clinical Trials Product Launch Dermatology Business Development R&d Clinical Development Pharmaceutics Drug Development Medical Affairs Hospitals

Benjamin Cowen, Phd, Mba Education Details

Frequently Asked Questions about Benjamin Cowen, Phd, Mba

What company does Benjamin Cowen, Phd, Mba work for?

Benjamin Cowen, Phd, Mba works for Immunomet Therapeutics, Inc.

What is Benjamin Cowen, Phd, Mba's role at the current company?

Benjamin Cowen, Phd, Mba's current role is Chief Executive Officer I Company Builder I Board Director.

What is Benjamin Cowen, Phd, Mba's email address?

Benjamin Cowen, Phd, Mba's email address is bc****@****met.com

What schools did Benjamin Cowen, Phd, Mba attend?

Benjamin Cowen, Phd, Mba attended Carnegie Mellon University - Tepper School Of Business, University Of Pennsylvania, University Of Illinois Urbana-Champaign, Brandeis University.

What are some of Benjamin Cowen, Phd, Mba's interests?

Benjamin Cowen, Phd, Mba has interest in Sailing, Skiing, Visiting National Parks, Enjoys Landscaping.

What skills is Benjamin Cowen, Phd, Mba known for?

Benjamin Cowen, Phd, Mba has skills like Pharmaceutical Industry, Biotechnology, Oncology, Strategy, Vaccines, Life Sciences, Cross Functional Team Leadership, Diabetes, Clinical Trials, Product Launch, Dermatology, Business Development.

Who are Benjamin Cowen, Phd, Mba's colleagues?

Benjamin Cowen, Phd, Mba's colleagues are Tingchen Cui.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.